Spinifex Pharmaceuticals

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014.

Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Spinifex Pharmaceuticals headquartered in Europe, operates in the Biotechnology, Health Care, Pharmaceutical sector. The company focuses on Biotechnology and has secured $3.7B in funding across 48 round(s). With a team of 11-50 employees, Spinifex Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Spinifex Pharmaceuticals, raised $19.2M. Discover more about their projects, partnerships, and impact on our platform.